Skip to main content
    I

    Ironwood Pharmaceuticals Inc (IRWD)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $4.85
    +0.02 (+0.41%)

    Market Cap: $799.61M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ironwood Pharmaceuticals Inc (IRWD) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Ironwood Pharmaceuticals (IRWD) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Ironwood Pharmaceuticals reported EPS of $0.36, above the $0.30 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    +22.62%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.37
    Range$0.33 - $0.41
    6 analysts
    Revenue Consensus
    $143.75M
    Range$133.87M - $152.46M
    6 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.31
    Range$0.26 - $0.35
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.30+3.4%
    60d ago$0.30+3.4%
    30d ago$0.30+3.4%
    7d ago$0.30+3.4%
    Current$0.31
    Revenue Consensus
    $108.90M
    Range$108.90M - $108.90M
    1 analysts

    Next Report

    IRWD has an expected report date of Feb 23, 2027.

    IRWD Earnings Call

    The latest IRWD earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, IRWD beat 20, missed 18 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $133.04M, up 9.0% from $122.06M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.36$0.30$0.30 - $0.32+20.00%Beat+50.0%21 up, 0 downNov 5, 2026$133.04M
    Jun 30, 2026$0.31$0.26N/A+19.23%Beat+121.4%20 up, 1 downAug 6, 2026$113.04M
    Mar 31, 2026$0.24$0.24$0.13 - $0.380.00%In lineN/A32 up, 0 downMay 7, 2026$106.51M
    Dec 31, 2025-$0.01$0.02N/A-159.52%Miss-150.0%20 up, 2 downFeb 25, 2026$47.71M
    Sep 30, 2025$0.24$0.12$0.09 - $0.14+100.00%Beat+1100.0%21 up, 1 downNov 10, 2025$122.06M
    Jun 30, 2025$0.14-$0.02N/A+800.00%BeatN/A21 up, 1 downAug 7, 2025$85.24M
    Mar 31, 2025-$0.14-$0.03N/A-366.67%MissN/A10 up, 0 downMay 7, 2025$41.14M
    Dec 31, 2024$0.02$0.08$0.03 - $0.16-74.19%MissN/A40 up, 0 downFeb 27, 2025$90.55M
    Sep 30, 2024$0.02$0.10$0.01 - $0.18-80.00%Miss-83.3%50 up, 0 downNov 7, 2024$91.59M
    Jun 30, 2024-$0.01$0.14$0.10 - $0.21-103.86%MissN/A60 up, 0 downAug 8, 2024$94.40M
    Mar 31, 2024-$0.02$0.15$0.10 - $0.48-113.33%Miss-108.0%60 up, 0 downMay 9, 2024$74.88M
    Dec 31, 2023-$0.01$0.20$0.13 - $0.39-105.00%Miss-103.7%60 up, 0 downFeb 15, 2024$117.55M
    Sep 30, 2023$0.12$0.16$0.12 - $0.25-25.00%Miss-57.1%40 up, 0 downNov 9, 2023$113.74M
    Jun 30, 2023-$6.71$0.25$0.23 - $0.26N/AN/A-3295.2%30 up, 0 downAug 8, 2023$107.38M
    Mar 31, 2023$0.25$0.24$0.23 - $0.27+4.17%Beat+19.0%41 up, 1 downMay 4, 2023$104.06M
    Dec 31, 2022$0.27$0.26$0.25 - $0.31+3.85%Beat0.0%50 up, 2 downFeb 16, 2023$107.20M
    Sep 30, 2022$0.28$0.27$0.25 - $0.28+3.70%Beat-15.2%41 up, 0 downNov 3, 2022$108.64M
    Jun 30, 2022$0.21$0.30$0.24 - $0.35-30.00%Miss-38.2%40 up, 0 downAug 4, 2022$97.23M
    Mar 31, 2022$0.21$0.26$0.22 - $0.27-19.23%Miss-12.5%40 up, 1 downMay 5, 2022$97.53M
    Dec 31, 2021$0.27$0.34$0.32 - $0.38-20.59%Miss-25.0%4N/AFeb 17, 2022$117.13M
    Sep 30, 2021$0.33$0.32$0.28 - $0.33+3.13%Beat+43.5%5N/ANov 4, 2021$103.75M
    Jun 30, 2021$0.34$0.22$0.21 - $0.25+54.55%Beat+112.5%5N/AAug 5, 2021$104.03M
    Mar 31, 2021$0.24$0.22$0.12 - $0.33+9.09%Beat+500.0%5N/AMay 6, 2021$88.84M
    Dec 31, 2020$0.36$0.29$0.22 - $0.37+24.14%Beat+20.0%5N/AFeb 17, 2021$116.68M
    Sep 30, 2020$0.23$0.15$0.11 - $0.17+53.33%Beat-42.5%5N/ANov 5, 2020$103.47M
    Jun 30, 2020$0.16$0.10$0.03 - $0.11+60.00%Beat+60.0%6N/AAug 6, 2020$89.43M
    Mar 31, 2020$0.04$0.05-$0.03 - $0.12-20.00%MissN/A5N/AMay 6, 2020$79.94M
    Dec 31, 2019$0.30$0.24$0.13 - $0.30+25.00%BeatN/A7N/AFeb 13, 2020$126.30M
    Sep 30, 2019$0.40$0.12$0.06 - $0.19+233.33%BeatN/A7N/AOct 31, 2019$131.17M
    Jun 30, 2019$0.10-$0.02-$0.19 - $0.06+600.00%BeatN/A7N/AJul 30, 2019$102.22M
    Mar 31, 2019-$0.26-$0.23-$0.27 - $0.10-13.04%MissN/A7N/AMay 2, 2019$68.73M
    Dec 31, 2018-$0.02-$0.19-$0.21 - $0.00+89.47%BeatN/A7N/AFeb 13, 2019$130.69M
    Sep 30, 2018-$0.38-$0.20-$0.21 - -$0.13-90.00%MissN/A7N/ANov 6, 2018$65.69M
    Jun 30, 2018-$0.28-$0.23-$0.27 - -$0.10-21.74%MissN/A9N/AAug 6, 2018$81.11M
    Mar 31, 2018-$0.27-$0.23-$0.29 - -$0.18-17.39%MissN/A7N/AMay 1, 2018$69.16M
    Dec 31, 2017-$0.14-$0.20-$0.25 - -$0.16+30.00%BeatN/A7N/AFeb 15, 2018$94.21M
    Sep 30, 2017-$0.18-$0.24-$0.29 - -$0.14+25.00%BeatN/A10N/ANov 2, 2017$86.83M
    Jun 30, 2017-$0.28-$0.23-$0.31 - -$0.15-21.74%MissN/A11N/AAug 3, 2017$65.08M
    Mar 31, 2017-$0.33-$0.21N/A-57.14%MissN/AN/AN/AMay 8, 2017$52.17M
    Dec 31, 2016-$0.09-$0.24N/A+62.50%BeatN/AN/AN/AFeb 21, 2017$87.46M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.23, up 1475.3% from the year before. It was -$0.51 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.23+1475.3%
    Dec 31, 2024$0.01N/A
    Dec 31, 2023-$6.35-754.6%
    Dec 31, 2022$0.97-17.8%
    Dec 31, 2021$1.18+49.4%
    Dec 31, 2020$0.79+46.3%
    Dec 31, 2019$0.54N/A
    Dec 31, 2018-$0.95N/A
    Dec 31, 2017-$0.93N/A
    Dec 31, 2016-$0.51N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,700 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,7269
    2026Q2Jun 30, 20264,37511
    2026Q1Mar 31, 20264,39910
    2025Q4Dec 31, 20254,69210
    2024Q4Dec 31, 20244,1479
    2024Q3Sep 30, 20243,4488
    2024Q2Jun 30, 20244,36711

    2026Q3 Earnings Call

    Opening remarks

    Chris Stamm VP of Investor Relations and Communications Good morning, and thanks for joining our third quarter 2026 investor update call. A press release issued this morning highlighting third quarter results can be found on our website. Today's call and accompanying slides include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially. A discussion of these statements and risk factors is available on the current safe harbor statement slide, as well as under the heading Risk Factors in our annual report on Form 10-K for the year ended December 31, 2025, and in our subsequent SEC filings. All forward-looking statements speak as of the date of this presentation, and we undertake no obligation to update such statements. Also included are non-GAAP financial measures, which should be considered only as a supplement to, and not a substitute for or superior to, GAAP measures. To the extent applicable, please refer to the tables at the end of our press release for reconciliations of these measures to the most directly comparable GAAP measures. During today's call, Chief Executive Officer Tom McCourt will review third quarter business highlights and our progress advancing our 2026 strategic priorities. Following Tom, Chief Commercial Officer and CEO-elect Tammi Gaskins will provide an overview of third quarter LINZESS performance. Next, Jeff Silber, our Chief Medical Officer and Head of Research and Drug Development, will provide an update on apraglutide and the STARS-2 trial. Ron Silver, our Interim Chief Financial Officer, will provide a financial update before turning the call back to Tom and Tammi for some closing remarks prior to opening the call for questions. Jeff Ruberti, Ironwood's Chief Strategy Officer, will also be available during the Q&A portion of the call. Today's webcast includes accompanying slides. For those joining by phone, please visit the Events section of our website to access the presentation. With that, I'll turn the call over to Tom.

    Tom McCourt CEO Thanks, Chris, and thank you all for joining us this morning to review Ironwood's third quarter 2026 financial results and business updates. Ironwood's momentum carried into the third quarter as we continued our focused execution across three strategic priorities: maximizing the value of LINZESS, advancing the development of apraglutide, and delivering sustained profits and cash flow. 2026 continues to be a turnaround year for the company as we make meaningful progress across each of these priorities. We believe LINZESS is on its way to returning to blockbuster status this year, demonstrating exceptional durability and growth in its 14th year on the market and remaining the leading U.S. branded prescription therapy for both IBS-C and chronic constipation.

    Frequently Asked Questions About IRWD

    When is Ironwood Pharmaceuticals's next earnings date?

    Ironwood Pharmaceuticals's next earnings report is expected for Feb 23, 2027.

    Did IRWD beat earnings estimates last quarter?

    Yes. Ironwood Pharmaceuticals reported EPS of $0.36 for the quarter ended Sep 30, 2026, above the $0.30 estimate, a 20.00% surprise.

    What EPS do analysts expect from IRWD next quarter?

    The consensus EPS estimate for Ironwood Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.37 from 6 analysts, with estimates from $0.33 to $0.41.

    How often does IRWD beat earnings estimates?

    Ironwood Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +42.36%.